bivalirudin
Generic: BIVALIRUDIN·Brand: ANGIOMAX, ANGIOMAX RTU, BIVALIRUDIN, BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
bivalirudin: sourced relationships with 1 company · 1 FDA decision.
bivalirudin evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect bivalirudin to MAIA; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could bivalirudin → MAIA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| MAIA Biotechnology, Inc. (MAIA) Reported 2019-07-25 · Current development: unknownSource | Approved |
| MAIA Biotechnology, Inc. (MAIA) Reported 2019-07-25 · Current development: unknownSource | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with bivalirudin?
bivalirudin has dated SEC/FDA relationship records for MAIA Biotechnology, Inc..
What is bivalirudin's latest FDA decision?
The most recent tracked FDA decision for bivalirudin is Approval, dated July 25, 2019.